1. "GSK Faculty"
Formats
  1. Journal Article (13834)
  2. Meeting Abstract (7076)
  3. Review (514)
  4. Book Section (342)
  5. Editorial (307)
  6. Conference Paper (162)
  7. Research Letter (96)
  8. Miscellaneous (45)
  9. Correspondence (38)
  10. Guidelines (32)
  11. Book Whole (22)
Groups
  1. GSK Faculty (22468)
  2. Sloan Kettering Institute Faculty (11482)
  3. Department of Medicine (10529)
  4. Tow Center for Developmental Oncology (TCDO) (6948)
  5. Sloan Kettering Institute Postdocs (6210)
  6. Solid Tumor Oncology Division (5880)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Steven Larson (957)
  3. Jedd Wolchok (905)
  4. Cristina Antonescu (895)
  5. Kenneth Offit (788)
  6. David Solit (779)

More People

Years
  1. 2025 (296)
  2. 2024 (868)
  3. 2023 (1016)
  4. 2022 (1152)
  5. 2021 (1088)
  6. 2020 (1257)

More Years

Publications
  1. Blood (1470)
  2. Journal of Clinical Oncology (1279)
  3. Cancer Research (1104)
  4. Clinical Cancer Research (527)
  5. Modern Pathology (494)
  6. Journal of Nuclear Medicine (474)

More Publications

Publishers
  1. Nature Publishing Group (2594)
  2. American Association for Cancer Research (2194)
  3. Elsevier Inc. (1937)
  4. American Society of Hematology (1553)
  5. Cell Press (1421)
  6. American Society of Clinical Oncology (1379)

More Publishers

Results (22468)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I/II study of SAR439859, an oral selective estrogen receptor degrader (SERD), in estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC)
    Meeting Abstract

    Campone, M.; Bardia, A.; Ulaner, G. A.; Chandarlapaty, S.; Gosselin, A.; Doroumian, S.; Pelekanou, V.; Celanovic, M.; Linden, H. M.
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase II study of MEK162 (binimetinib [BINI]) in combination with imatinib in patients with untreated advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Chi, P.; Qin, L. X.; Kelly, C. M.; D'Angelo, S. P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Movva, S.; Nacev, B.; Crago, A. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Characterization of patients with multiple primary tumors
    Meeting Abstract

    Cadoo, K. A.; Mukherjee, S.; Khurram, A.; Kemel, Y.; Tkachuk, K.; Liu, Y. L.; Carlo, M. I.; Walsh, M. F.; Latham, A.; Dubard-Gault, M. E.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Radioiodine (RAI) in combination with durvalumab for recurrent/metastatic thyroid cancers
    Meeting Abstract

    Burman, B.; Sherman, E. J.; Kriplani, A.; Michel, L. S.; Dunn, L.; Fetten, J. V.; Warner, E.; Grewal, R. K.; Sabra, M.; Tuttle, R. M.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • The impact of poly ADP ribose polymerase (PARP) inhibitors on clonal hematopoiesis
    Meeting Abstract

    Bolton, K. L.; Moukarzel, L. A.; Ptashkin, R.; Gao, T.; Patel, M.; Caltabellotta, N.; Braunstein, L. Z.; Aghajanian, C.; Hyman, D. M.; Berger, M. F.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Prevalence and tissue concordance of BRCA2 copy number loss evaluated by single-cell, shallow whole genome sequencing of circulating tumor cells (CTCs) in castration-resistant prostate cancer (CRPC)
    Meeting Abstract

    Barnett, E.; Schonhoft, J.; Schultz, N. D.; Lee, J.; Zaidi, S.; Abida, W.; Carmichael, T.; Dago, A. E.; Solit, D. B.; Wenstrup, R.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Prevalence and characterization of dermatologic adverse events related to alpelisib (BYL719) in breast cancer patients
    Meeting Abstract

    Barrios, D. M.; Wang, D. G.; Blinder, V. S.; Bromberg, J.; Drullinsky, P.; Funt, S. A.; Jhaveri, K. L.; Lake, D.; Lyons, T.; Modi, S.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Clinical characteristics and anti-PD-(L)1 treatment outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer
    Meeting Abstract

    Arbour, K. C.; Rizvi, H.; Plodkowski, A. J.; Halpenny, D.; Hellmann, M. D.; Heller, G.; Knezevic, A.; Yu, H. A.; Ladanyi, M.; Kris, M. G.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Healing early signals in wound healing
    Meeting Abstract

    Niethammer, P.
    FASEB Journal (2020)

    Fulltext@MSK | Save
  • Uncovering how RAD51C mutations contribute to cancer predisposition and sensitize to chemotherapeutics
    Meeting Abstract

    Sullivan, M. R.; Prakash, R.; Rawal, Y.; Grundy, M. K.; Baird, J. M.; Mihalevic, M. J.; Rein, H.; Garcin, E. B.; Wang, R.; Modesti, M.; more...
    Environmental and Molecular Mutagenesis (2020)

    Fulltext@MSK | Save